埃莫帕米尔结合蛋白抑制剂用于治疗多发性硬化症
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
ACS medicinal chemistry letters
|November 17, 2023
概括
抑制乳胺结合蛋白 (EBP) 的新型化合物在治疗多发性硬化症方面表现有前途. 这项研究详细介绍了新的EBP抑制剂,它们的制药用途和制备方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
- 埃莫帕米尔结合蛋白 (EBP) 在胆固醇生物合成中起作用,并与神经系统疾病有关.
- 目前对多发性硬化症的治疗有局限性,需要开发新的治疗策略.
研究的目的:
- 为了引入新型的抑制剂的埃莫帕米尔结合蛋白 (EBP).
- 描述含有这些EBP抑制剂的药物成分.
- 概述这些化合物在多发性硬化症治疗中的使用及其制备.
主要方法:
- 针对EBP的新化学实体的合成和表征.
- 药物成分的配方,包括已识别的EBP抑制剂.
- 在体外和/或体内研究以评估多发性硬化症相关模型中的化合物的疗效和安全性.
主要成果:
- 强效和选择性的乳胺结合蛋白 (EBP) 抑制剂的鉴定.
- 在多发性硬化症的临床前模型中证明这些抑制剂的治疗潜力.
- 开发可扩展的过程,用于制备新型化合物.
结论:
- 新型EBP抑制剂代表了对多发性硬化症治疗的有前途的新疗法.
- 这些化合物为管理MS提供了潜在的新机制.
- 需要进一步的研究和临床开发来确定它们的治疗价值.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
188
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
188
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
317
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
317
Antiepileptic Drugs: Glutamate Antagonists
380
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
380
Antiepileptic Drugs: Calcium Channel Blockers
417
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
417
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
845
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
845
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K


